HIMS

29.42

0.48% 0.14

Vorhandelsmarkt: 29.02 -0.40 -1.36%

Hims Hers Health Inc (HIMS)

Überblick Nachrichten Preisverlauf Optionskette Financials Warum fällt HIMS? Forum Prognose

Schlusskurs vom Vortag:

$29.28

Offen:

$29.48

24-Stunden-Volumen:

8.18M

Relative Volume:

0.64

Marktkapitalisierung:

$6.86B

Einnahmen:

$2.35B

Nettoeinkommen (Verlust:

$128.37M

KGV:

56.35

EPS:

0.5221

Netto-Cashflow:

$57.42M

1W Leistung:

+5.11%

1M Leistung:

-7.34%

6M Leistung:

+41.17%

1J Leistung:

-46.38%

1-Tages-Spanne:

$28.57

$29.76

1-Wochen-Bereich:

$27.31

$31.81

52-Wochen-Spanne:

$13.74

$65.30

Hims Hers Health Inc Stock (HIMS) Company Profile

Firmenname

Hims Hers Health Inc

Sektor

Healthcare (1067)

Branche

Drug Manufacturers - Specialty & Generic (87)

Telefon

415-851-0195

Adresse

2269 CHESTNUT ST, SAN FRANCISCO

Mitarbeiter

2,442

Twitter

Nächster Verdiensttermin

2026-11-02

Neueste SEC-Einreichungen

HIMS's Discussions on Twitter

Compare HIMS vs TAK, TEVA, HLN, ZTS, VTRS

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
HIMS Hims Hers Health Inc	29.42	6.86B	2.35B	128.37M	57.42M	0.5221
TAK Takeda Pharmaceutical Co Adr	18.86	60.23B	29.91B	1.30B	3.49B	0.4056
TEVA Teva Pharmaceutical Industries Ltd Adr	39.19	45.71B	17.53B	1.58B	444.18M	1.3457
HLN Haleon Plc Adr	9.26	40.72B	14.54B	2.22B	2.58B	0.4871
ZTS Zoetis Inc	71.05	29.36B	9.51B	2.64B	2.14B	6.0361
VTRS Viatris Inc	17.83	20.48B	14.57B	-296.50M	1.64B	-0.259

Hims Hers Health Inc Stock (HIMS) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2026-04-24	Eingeleitet	JP Morgan	Overweight
2026-03-10	Hochstufung	BofA Securities	Underperform → Neutral
2026-03-10	Hochstufung	Citigroup	Sell → Neutral
2026-03-09	Hochstufung	Needham	Hold → Buy
2026-02-24	Herabstufung	BTIG Research	Buy → Neutral
2026-01-12	Eingeleitet	Evercore ISI	In-line
2025-12-09	Eingeleitet	Barclays	Overweight
2025-10-21	Eingeleitet	KeyBanc Capital Markets	Sector Weight
2025-06-23	Herabstufung	Needham	Buy → Hold
2025-06-04	Bestätigt	Needham	Buy
2025-04-29	Herabstufung	TD Cowen	Buy → Hold
2025-02-18	Herabstufung	Morgan Stanley	Overweight → Equal-Weight
2025-01-10	Herabstufung	Citigroup	Neutral → Sell
2025-01-07	Eingeleitet	BTIG Research	Buy
2024-12-17	Eingeleitet	Morgan Stanley	Overweight
2024-11-14	Herabstufung	BofA Securities	Buy → Underperform
2024-08-22	Eingeleitet	Needham	Buy
2024-08-09	Herabstufung	Imperial Capital	Outperform → In-line
2024-05-22	Herabstufung	Citigroup	Buy → Neutral
2024-04-16	Herabstufung	Jefferies	Buy → Hold
2024-04-10	Eingeleitet	Canaccord Genuity	Buy
2024-02-28	Hochstufung	Imperial Capital	In-line → Outperform
2024-02-26	Eingeleitet	Leerink Partners	Market Perform
2023-12-07	Eingeleitet	Imperial Capital	In-line
2023-07-28	Eingeleitet	TD Cowen	Outperform
2023-04-11	Eingeleitet	Robert W. Baird	Neutral
2023-02-09	Hochstufung	Jefferies	Hold → Buy
2022-11-08	Hochstufung	BofA Securities	Neutral → Buy
2022-11-08	Hochstufung	SVB Leerink	Mkt Perform → Outperform
2022-10-17	Herabstufung	Piper Sandler	Overweight → Neutral
2022-09-07	Eingeleitet	Truist	Hold
2022-07-15	Eingeleitet	SVB Leerink	Underperform
2022-04-14	Eingeleitet	Guggenheim	Buy
2022-04-01	Fortgesetzt	Credit Suisse	Outperform
2022-03-10	Eingeleitet	Deutsche Bank	Hold
2021-12-02	Eingeleitet	Jefferies	Hold
2021-11-11	Hochstufung	Piper Sandler	Neutral → Overweight
2021-07-06	Eingeleitet	BofA Securities	Neutral
2021-05-20	Hochstufung	Credit Suisse	Neutral → Outperform
2021-04-21	Eingeleitet	Truist	Hold
2021-03-09	Eingeleitet	Credit Suisse	Neutral
2021-03-02	Hochstufung	Citigroup	Neutral → Buy
2021-02-17	Eingeleitet	Citigroup	Neutral
2021-02-12	Eingeleitet	Piper Sandler	Neutral
2021-02-08	Eingeleitet	Tigress Financial	Buy

Alle ansehen

Hims Hers Health Inc Aktie (HIMS) Neueste Nachrichten

Sep 27, 2026

Form 144 Hims & Hers Health For: 27 September By Investing.com - Investing.com Nigeria

Sep 27, 2026

HIMS Investors Have Opportunity to Lead Hims & Hers Health, Inc. Securities Fraud Lawsuit - Morningstar

Sep 27, 2026

Form 4 Hims Hers Health Inc For: 26 September By Investing.com - Investing.com Nigeria

Sep 27, 2026

Sep 26, 2026

Hims & Hers CFO Okupe sells $876,846 of HIMS stock - Investing.com

Sep 26, 2026

Hims & Hers Health (HIMS) Unveils AI Native Weight Loss Care Platform - Yahoo Finance

Sep 26, 2026

Shareholders who lost money in shares of acquired Hims & - GlobeNewswire

Sep 26, 2026

Sep 25, 2026

Kaplan Fox Advises Hims & Hers Health, Inc. (NYSE: HIMS) Investor - The National Law Review

Sep 25, 2026

Hims & Hers Health, Inc. Securities Fraud Class Action Result of Deceptive Privacy and Billing Practices and Over 14% Stock DeclineInvestors may Contact Lewis Kahn, Esq., at Kahn Swick & Foti, LLC - morningstar.com

Sep 25, 2026

2 Reasons to Like HIMS (and 1 Not So Much) - Yahoo Finance

Sep 25, 2026

ROSEN, SKILLED INVESTOR COUNSEL, Encourages Hims & Hers Health, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - GlobeNewswire Inc.

Sep 25, 2026

HIMS Investor Alert: Kessler Topaz Meltzer & Check, LLP Encourages HIMS Investors with Losses to Contact the Firm - GlobeNewswire

Sep 25, 2026

HIMS Investor Alert: Kessler Topaz Meltzer & Check, LLP Encourages HIMS Investors with Losses to Contact the Firm - GlobeNewswire Inc.

Sep 25, 2026

HIMS Stockholders Have Rights – If You Lost Money Investing - GlobeNewswire

Sep 25, 2026

HIMS Investors Have Opportunity to Lead Hims & Hers Health, Inc. Securities Fraud Lawsuit with SBS Law - GlobeNewswire

Sep 25, 2026

Sep 24, 2026

INVESTOR DEADLINE: Hims & Hers Health, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit Before November 2, 2026 DeadlineHIMS - TMX Newsfile

Sep 24, 2026

Hims Launches AI-Native Weight Loss Care Platform Featuring Closed-Loop Action Engine and Clinical Escalation - HIT Consultant

Sep 24, 2026